Adherium Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Paul Mastoridis

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	8.4yrs

Recent management updates

Recent updates

CEO

Paul Mastoridis

less than a year

Tenure

Dr. Paul Mastoridis is Chief Executive Officer of Adherium Limited from February 2024. Paul Mastoridis has many years experience in the pharmaceutical industry, pioneering and leading digital solutions in...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Louis Panaccio	Executive Chairman of the Board	2.3yrs	AU$110.50k	0.39% A$ 26.7k
Daniel Kaplon	Chief Financial Officer	1.6yrs	AU$305.22k	no data
Rick Legleiter	Executive Officer	less than a year	AU$463.90k	no data
Brett Tucker	Company Secretary	less than a year	AU$66.74k	no data
Paul Mastoridis	Chief Executive Officer	less than a year	no data	no data
Francis White	Chief Operating Officer	less than a year	no data	no data
Chris Leigh-Lancaster	VP of Product & Technology	less than a year	no data	no data
Cassandra Thomas	Vice President of People and Culture	less than a year	no data	no data
Michael Motion	Consultant	3yrs	AU$1.14m	no data
Zoe Park	Head of Software	less than a year	no data	no data
Nancy She	Head of Supply Chain and Procurement	less than a year	no data	no data
Michael Gormack	Head of Devices	less than a year	no data	no data

0.3yrs

Average Tenure

63yo

Average Age

Experienced Management: ADR's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Louis Panaccio	Executive Chairman of the Board	2.3yrs	AU$110.50k	0.39% A$ 26.7k
Bruce McHarrie	Independent Non-Executive Director	8.8yrs	AU$55.25k	0.054% A$ 3.7k
William Hunter	Independent Non-Executive Director	8.4yrs	AU$50.00k	0.061% A$ 4.1k
Jeremy Curnock-Cook	Independent Non-Executive Director	9.1yrs	AU$50.00k	0.053% A$ 3.6k
George Baran	Non-Executive Director	3yrs	AU$50.00k	no data

8.4yrs

Average Tenure

65yo

Average Age

Experienced Board: ADR's board of directors are considered experienced (8.4 years average tenure).

Adherium Management

Management criteria checks 1/4

Key information

Recent management updates

Adherium Limited, Annual General Meeting, Nov 30, 2023

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Recent updates

Adherium Limited has filed a Follow-on Equity Offering in the amount of AUD 1.57 million.

New minor risk - Shareholder dilution

New major risk - Financial position

New major risk - Market cap size

New major risk - Market cap size

Adherium Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$0.002 loss per share (vs AU$0.005 loss in FY 2022)

New major risk - Financial position

New minor risk - Financial data availability

New major risk - Revenue size

Adherium Limited Announces Resignation of Mark Licciardo as Joint Company Secretary

Adherium Limited Announces Executive Changes

Adherium Limited Commences Production and Market Release of the New, Next Generation Ellipta Sensor

Adherium Limited Receives Australian Therapeutic Goods Administration Approval for Next Generation Sensors

Adherium Announces James Ward-Lilley Step Down from the Board

Adherium Limited Receives U.S. FDA 510(k) Clearance for GSK pMDI Inhaler Users to Remotely Monitor Physiological Parameters

Adherium Limited, Annual General Meeting, Nov 29, 2022

Adherium Limited Appoints Daniel Kaplon as Chief Financial Officer, Effective 10 October 2022

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.017 loss in FY 2021)

Adherium Limited Submits FDA 510(K) Application for Next Generation Hailie Sensor for Teva MDI Inhalers

Adherium Limited Submits US FDA Application for Hailie for GSK pMDI inhalers

Adherium Limited Receives U.S. Food and Drug Administration Clearance for Hailie for Ellipta

Adherium Limited Announces Conclusion of Robert Spurr's Assignment as Interim CFO

Adherium Limited Releases Next Gen Platform Integration Services

Adherium Limited Submits US FDA 510(k) Application for Ellipta Inhaler Users to Connect to Hailie Platform with Physiological Parameters

Adherium Limited Announces Board Changes

Adherium Limited Announces That Manufacturing Started for Hailie® for Symbicort® Sensors with Physiological Parameters

Adherium Submits US FDS 510(k) Application for Next Generation Hailie Sensor with Physiological Measures

Adherium Limited announced that it expects to receive AUD 3 million in funding from Trudell Medical Limited, Bioscience Managers Pty Ltd

Independent Non-Executive Director has left the company

Adherium Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.036 loss per share

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age